Tracking of serum lipid levels, blood pressure, and body mass index from childhood to adulthood: the Cardiovascular Risk in Young Finns Study. J Pediatr. 2011;159:584 90. S4.4.4.3-41. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guide- lines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011;128 suppl 5: S213 56. S4.4.4.3-42. Gidding SS, Daniels SR, Kavey RE, et al. Developing the 2011 integrated pediatric guidelines for cardiovascular risk reduction. Pediatrics. 2012;129:e1311 9. 4.5. Other Populations at Risk S4.5.1-1. Carnethon MR, Pu J, Howard G, et al. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. Circulation. 2017;136:e393 423. abnormalities among normal-weight persons from five racial/eth- nic groups in the United States: a cross-sectional analysis of two cohort studies. Ann Intern Med. 2017;166:628 36. S4.5.1-3. Rao G, Powell-Wiley TM, Ancheta I, et al. Identification of obesity and cardiovascular risk in ethnically and racially diverse popula- tions: a scientific statement from the American Heart Association. Circulation. 2015;132:457 72. S4.5.1-4. Hata J, Kiyohara Y. Epidemiology of stroke and coronary artery disease in Asia. Circ J. 2013;77:1923 32. S4.5.1-5. Group H-TC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279 91. S4.5.1-6. Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refin- ing myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155 62. S4.5.1-7. 